LNP-RNA Therapeutics: Size, Concentration, Payload, And Quality With Light Scattering

The therapeutic potential of lipid nanoparticles (LNPs) as delivery vehicles has been demonstrated in recent years, with mRNA-based COVID-19 vaccines an outstanding example of global benefit. In order to ensure the safety and efficacy of an LNP-RNA vaccine or therapeutic, multiple quality attributes of LNP-RNA products need to be measured throughout the product development cycle. This webinar will review the use of two essential technologies for biophysical characterization and screening of LNP-RNA products.

Dynamic light scattering (DLS) in an automated plate reader effectively performs fast screening and quality control of LNP preparations. Multi-angle light scattering combined with ultraviolet (UV) and refractive index (dRI) detectors, following separation by either size-exclusion chromatography (SEC-MALS) or field-flow fractionation (FFF-MALS), provides in-depth characterization. Case studies cover the quantitation of particle size distribution, particle concentration, the molecular weight of RNA and LNP in each eluting fraction, and sized-based RNA payload distribution of the LNP formulation.

In this webinar we review a method for charaterizing and quantifying lipid nanoparticle formualtions for nucleic acid therapeutics. The method quantifies LNP size, concentration and other quality attributes.